EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 332 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Reflecting On My Time As the Cancer.Net Editor in Chief May 26, 2021 Disease in a dish: Mini-gut organoids and the challenges of bowel... February 11, 2022 Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC April 19, 2022 Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... October 4, 2022 Load more HOT NEWS Hormone therapy gets green light for advanced prostate cancer Study Adds to Debate about Mammography in Older Women ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in...
